Drug Trial Radar · NCT03414658
The AVIATOR Study: Trastuzumab and Vinorelbine With Avelumab OR Avelumab & Utomilumab in Advanced HER2+ Breast Cancer
Last checked: Nov 19, 2026Latest source record: Jul 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
100
Actual
Start
Jun 21, 2018
Primary completion
May 1, 2023
Study completion May 31, 2027
Sponsor
- Lead sponsor
- Adrienne G. WaksAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Pfizer; Breast Cancer Research Foundation; Johns Hopkins University
- First posted
- Jan 30, 2018
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This research study is studying a combination of drugs as a possible treatment for breast cancer. The drugs involved in this study are: * Group A: Trastuzumab (Herceptin) + Vinorelbine (Navelbine) * Group B: Trastuzumab + Vinorelbine + Avelumab * Group C: Trastuzumab + Vinorelbine + Avelumab + Utomilumab (PF-05082566)
Conditions
- Breast Cancer
Interventions
VinorelbineDrug
work by interfering with cell division, which leaves the tumor unable to grow and spread
TrastuzumabDrug
trastuzumab induces an antibody-dependent cell-mediated cytotoxicity against tumor cells that overexpress HER2.
AvelumabDrug
monoclonal antibody directed against the human immunosuppressive ligand programmed death-ligand 1 (PD-L1) protein
UtomilumabDrug
Utomilumab is an antibody designed to stimulate the body's immune system to fight cancer cells
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression Free SurvivalTime frame: 2 years
Locations
17 sites in 1 country. Site status is shown where the registry gives one.
University of Alabama at Birmingham
Birmingham, Alabama
University of California San Francisco
San Francisco, California
Georgetown University Medical Center
Washington D.C., District of Columbia
University of Chicago Medical Center
Chicago, Illinois
Indiana University Health Melvin and Bren Simon Cancer Center
Indianapolis, Indiana
Johns Hopkins University
Baltimore, Maryland
Beth Israel Deaconess Medical Center
Boston, Massachusetts
Dana-Farber Cancer Institute
Boston, Massachusetts
Memorial Sloan-Kettering Cancer Center
New York, New York
Montefiore Medical Center
The Bronx, New York
University of Carolina at Chapel Hill
Chapel Hill, North Carolina
Duke University Medical Center
Durham, North Carolina
University of Pennsylvania
Philadelphia, Pennsylvania
Vanderbilt University Medical Center
Nashville, Tennessee
Baylor College of Medicine
Houston, Texas
MD Anderson Cancer Center
Houston, Texas
University of Washington Fred Hutchinson Cancer Care
Seattle, Washington
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.